210 related articles for article (PubMed ID: 37671815)
21. Tyrosine kinase inhibitors rechallenge in solid tumors: a review of literature and a case description with lenvatinib in thyroid cancer.
Felicetti F; Nervo A; Piovesan A; Berardelli R; Marchisio F; Gallo M; Arvat E
Expert Rev Anticancer Ther; 2017 Dec; 17(12):1093-1098. PubMed ID: 28988510
[TBL] [Abstract][Full Text] [Related]
22. SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer.
Kim SY; Kim SM; Chang HJ; Kim BW; Lee YS; Park CS; Park KC; Chang HS
BMC Cancer; 2018 Oct; 18(1):956. PubMed ID: 30286728
[TBL] [Abstract][Full Text] [Related]
23. Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR-MAPK cascades.
Hoshi T; Watanabe Miyano S; Watanabe H; Sonobe RMK; Seki Y; Ohta E; Nomoto K; Matsui J; Funahashi Y
Biochem Biophys Res Commun; 2019 May; 513(1):1-7. PubMed ID: 30944079
[TBL] [Abstract][Full Text] [Related]
24. Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma.
Yamauchi M; Ono A; Ishikawa A; Kodama K; Uchikawa S; Hatooka H; Zhang P; Teraoka Y; Morio K; Fujino H; Nakahara T; Murakami E; Miki D; Kawaoka T; Tsuge M; Hiramatsu A; Imamura M; Hayes CN; Fujita M; Nakagawa H; Yasui W; Aikata H; Chayama K
Clin Transl Gastroenterol; 2020 May; 11(5):e00179. PubMed ID: 32677805
[TBL] [Abstract][Full Text] [Related]
25. Epidermal growth factor receptor activation confers resistance to lenvatinib in thyroid cancer cells.
Ohno K; Shibata T; Ito KI
Cancer Sci; 2022 Sep; 113(9):3193-3210. PubMed ID: 35723021
[TBL] [Abstract][Full Text] [Related]
26. Multitargeting strategy using lenvatinib and golvatinib: maximizing anti-angiogenesis activity in a preclinical cancer model.
Nakazawa Y; Kawano S; Matsui J; Funahashi Y; Tohyama O; Muto H; Nakagawa T; Matsushima T
Cancer Sci; 2015 Feb; 106(2):201-7. PubMed ID: 25458359
[TBL] [Abstract][Full Text] [Related]
27. Lenvatinib: first global approval.
Scott LJ
Drugs; 2015 Apr; 75(5):553-60. PubMed ID: 25795101
[TBL] [Abstract][Full Text] [Related]
28. Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression.
Fu R; Jiang S; Li J; Chen H; Zhang X
Med Oncol; 2020 Mar; 37(4):24. PubMed ID: 32166604
[TBL] [Abstract][Full Text] [Related]
29. Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer.
Cabanillas ME; Takahashi S
Semin Oncol; 2019 Feb; 46(1):57-64. PubMed ID: 30685073
[TBL] [Abstract][Full Text] [Related]
30. Drug safety evaluation of lenvatinib for thyroid cancer.
Krajewska J; Kukulska A; Jarzab B
Expert Opin Drug Saf; 2015; 14(12):1935-43. PubMed ID: 26484847
[TBL] [Abstract][Full Text] [Related]
31. A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer.
Schlumberger M; Jarzab B; Cabanillas ME; Robinson B; Pacini F; Ball DW; McCaffrey J; Newbold K; Allison R; Martins RG; Licitra LF; Shah MH; Bodenner D; Elisei R; Burmeister L; Funahashi Y; Ren M; O'Brien JP; Sherman SI
Clin Cancer Res; 2016 Jan; 22(1):44-53. PubMed ID: 26311725
[TBL] [Abstract][Full Text] [Related]
32. Lenvatinib as a therapy for unresectable hepatocellular carcinoma.
Spallanzani A; Orsi G; Andrikou K; Gelsomino F; Rimini M; Riggi L; Cascinu S
Expert Rev Anticancer Ther; 2018 Nov; 18(11):1069-1076. PubMed ID: 30220234
[TBL] [Abstract][Full Text] [Related]
33. EGFR activation limits the response of liver cancer to lenvatinib.
Jin H; Shi Y; Lv Y; Yuan S; Ramirez CFA; Lieftink C; Wang L; Wang S; Wang C; Dias MH; Jochems F; Yang Y; Bosma A; Hijmans EM; de Groot MHP; Vegna S; Cui D; Zhou Y; Ling J; Wang H; Guo Y; Zheng X; Isima N; Wu H; Sun C; Beijersbergen RL; Akkari L; Zhou W; Zhai B; Qin W; Bernards R
Nature; 2021 Jul; 595(7869):730-734. PubMed ID: 34290403
[TBL] [Abstract][Full Text] [Related]
34. Lenvatinib: A Review in Refractory Thyroid Cancer.
Frampton JE
Target Oncol; 2016 Feb; 11(1):115-22. PubMed ID: 26867945
[TBL] [Abstract][Full Text] [Related]
35. Lenvatinib for the treatment of renal cell carcinoma.
Roviello G; Corona SP; Bozza G; Aieta M; Generali D; Rodriquenz MG; Mileo AM; Imperatori M; Ianza A; Conca R; Sobhani N
Expert Opin Investig Drugs; 2018 May; 27(5):507-512. PubMed ID: 29718721
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological and clinical profile of lenvatinib (E-7080) in the treatment of advanced, radioiodine-refractory, differentiated thyroid cancer.
Hegazi M; Azadi A; Jain D; Redman R; Perez CA
Drugs Today (Barc); 2015 Dec; 51(12):689-94. PubMed ID: 26798849
[TBL] [Abstract][Full Text] [Related]
37. The immunomodulatory activity of lenvatinib prompts the survival of patients with advanced hepatocellular carcinoma.
Zhu J; Fang P; Wang C; Gu M; Pan B; Guo W; Yang X; Wang B
Cancer Med; 2021 Nov; 10(22):7977-7987. PubMed ID: 34605616
[TBL] [Abstract][Full Text] [Related]
38. Real-World Efficacy and Safety of Multi-Tyrosine Kinase Inhibitors in Radioiodine Refractory Thyroid Cancer.
Koehler VF; Berg E; Adam P; Weber GL; Pfestroff A; Luster M; Kutsch JM; Lapa C; Sandner B; Rayes N; Fuss CT; Kreissl MC; Hoster E; Allelein S; Schott M; Todica A; Fassnacht M; Kroiss M; Spitzweg C
Thyroid; 2021 Oct; 31(10):1531-1541. PubMed ID: 34405734
[No Abstract] [Full Text] [Related]
39. Advances in pharmacotherapy for advanced thyroid cancer of follicular origin (PTC, FTC). New approved drugs and future therapies.
Elia G; Ferrari SM; Ragusa F; Paparo SR; Mazzi V; Ulisse S; Benvenga S; Antonelli A; Fallahi P
Expert Opin Pharmacother; 2022 Apr; 23(5):599-610. PubMed ID: 35038965
[TBL] [Abstract][Full Text] [Related]
40. Lenvatinib in Advanced, Radioactive Iodine-Refractory, Differentiated Thyroid Carcinoma.
Yeung KT; Cohen EE
Clin Cancer Res; 2015 Dec; 21(24):5420-6. PubMed ID: 26487760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
